Interleukin-10 (IL-10): An update on its relevance for cardiovascular risk

Nephrology Dialysis Transplantation

Volumn 18, Issue 10, 2003, Pages 1976-1979

  Girndt, Matthias ^a   Köhler, Hans ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Atherosclerosis; Chronic renal failure; End stage renal disease; Inflammation; Interleukin 10

Indexed keywords

INTERLEUKIN 10;

ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; DISEASE COURSE; DISEASE SEVERITY; DOWN REGULATION; EDITORIAL; ENDOTHELIUM INJURY; GENETIC VARIABILITY; HUMAN; INFLAMMATION; LIPID METABOLISM; MEDIATOR; NONHUMAN; PREDICTION; PRIORITY JOURNAL; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CORONARY ARTERIOSCLEROSIS; DOWN-REGULATION; FEMALE; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-10; KIDNEY FAILURE, CHRONIC; MALE; PROGNOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS;

EID: 0141507033     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfg311     Document Type: Editorial

References (30)

1. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-126
2. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-979
3. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347: 1557-1565
4. Schieffer B, Schieffer E, Hilfiker-Kleiner D et al. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation 2000; 101: 1372-1378
5. Galis ZS, Asanuma K, Godin D, Meng X. N-Acetyl-cysteine decreases the matrix-degrading capacity of macrophage-derived foam cells: new target for antioxidant therapy? Circulation 1998; 97: 2445-2453
6. Munford RS. Statins and the acute-phase response. N Engl J Med 2001; 344: 2016-2018
7. Varadhachary AS, Monestier M, Salgame P. Reciprocal induction of IL-10 and IL-12 from macrophages by low-density lipoprotein and its oxidized forms. Cell Immunol 2001; 213: 45-51
8. Fu T, Borensztajn J. Macrophage uptake of low-density lipoprotein bound to aggregated C-reactive protein: possible mechanism of foam-cell formation in atherosclerotic lesions. Biochem J 2002; 366: 195-201
9. Kiechl S, Egger G, Mayr M et al. Chronic infections and the risk of carotid atherosclerosis: prospective results from a large population study. Circulation 2001; 103: 1064-1070
10. de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991; 174: 1209-1220
11. Mallat Z, Heymes C, Ohan J et al. Expression of interleukin-10 in advanced human atherosclerotic plaques: relation to inducible nitric oxide synthase expression and cell death. Arterioscler Thromb Vasc Biol 1999; 19: 611-616
12. Von der Thüsen JH, Kuiper J, Fekkes ML et al. Attenuation of atherogenesis by systemic and local adenovirus-mediated gene transfer of interleukin-10 in LDLr-/- mice. FASEB J 2001; 15: 2730-2732
13. Mallat Z, Besnard S, Duriez M et al. Protective role of interleukin-10 in atherosclerosis. Circ Res 1999; 85: e17-e24
14. Mostafa ME, Chollet-Martin S, Oudghiri M et al. Effects of interleukin-10 on monocyte/endothelial cell adhesion and MMP-9/TIMP-1 secretion. Cardiovasc Res 2001; 49: 882-890
15. Lacraz S, Nicod LP, Chicheportiche R, Welgus HG, Dayer JM. IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. J Clin Invest 1995; 96: 2304-2310
16. Waehre T, Halvorsen B, Damas JK et al. Inflammatory imbalance between IL-10 and TNFalpha in unstable angina potential plaque stabilizing effects of IL-10. Eur J Clin Invest 2002; 32: 803-810
17. Smith DA, Irving SD, Sheldon J, Cole D, Kaski JC. Serum levels of the antiinflammatory cytokine interleukin-10 are decreased in patients with unstable angina. Circulation 2001; 104: 746-749
18. Turner DM, Williams DM, Sankaran D et al. An investigation of polymorphism in the interleukin-10 gene promotor. Eur J Immunogen 1997; 24: 1-8
19. Koch W, Kastrati A, Bottiger C et al. Interleukin-10 and tumor necrosis factor gene polymorphisms and risk of coronary artery disease and myocardial infarction. Atherosclerosis 2001; 159: 137-144
20. Donger C, Georges JL, Nicaud V et al. New polymorphisms in the interleukin-10 gene - relationships to myocardial infarction. Eur J Clin Invest 2001; 31: 9-14
21. Canivet E, Lavaud S, Wong T et al. Cuprophane but not synthetic membrane induces increases in serum tumor necrosis factor-alpha levels during hemodialysis. Am J Kidney Dis 1994; 23: 41-46
22. Bologa RM, Levine DM, Parker TS et al. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis 1998; 32: 107-114
23. Girndt M, Sester U, Kaul H, Köhler H. Production of proinflammatory and regulatory monokines in hemodialysis patients shown at a single cell level. J Am Soc Nephrol 1998; 9: 1689-1696
24. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32: S112-S119
25. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999; 55: 648-658
26. Girndt M, Köhler H, Schiedhelm Weick E et al. Production of interleukin-6, tumor necrosis factor alpha and interleukin-10 in vitro correlates with the clinical immune defect in chronic hemodialysis patients. Kidney Int 1995; 47: 559-565
27. Morita Y, Yamamura M, Kashihara N, Makino H. Increased production of interleukin-10 and inflammatory cytokines in blood monocytes of hemodialysis patients. Res Commun Mol Pathol Pharmacol 1997; 98: 19-33
28. Brunet P, Capo C, Dellacasagrande J et al. IL-10 synthesis and secretion by peripheral blood mononuclear cells in haemodialysis patients. Nephrol Dial Transplant 1998; 13: 1745-1751
29. Girndt M, Sester U, Sester M et al. The interleukin-10 promotor genotype determines clinical immune function in hemodialysis patients. Kidney Int 2001; 60: 2385-2391
30. Girndt M, Kaul H, Sester U et al. Anti-inflammatory interleukin-10 genotype protects dialysis patients from cardiovascular events. Kidney Int 2002; 62: 949-955